Improving the Reimbursement Process for New Drugs: A Case Study of a Two‐Waiver System in South Korea

This study demonstrates how Korea's two-waiver system streamlined the reimbursement process, improving access to orphan and cancer drugs while ensuring financial sustainability. The system's eligibility criteria effectively balance the needs of noncritical and critical diseases, ensuring equitable access while maintaining fiscal responsibility. These findings have important institutional implications for improving patient access to medicines while effectively managing financial expenditure.